Pharmaceuticals, Biotechnology & Life Sciences

Genmab‑Incyte’s KRAS‑targeted ADC partnership and Incyte’s IBI3001/IBI354 pipeline show how precision oncology can boost valuation, navigate patent cliffs and spark future M&A.

Roivant Sciences to report Q4 earnings: robust 100%+ revenue growth but modest EPS decline expected, highlighting a widening gap between top‑line expansion and profitability.

Discover how AstraZeneca’s new sone‑ve therapy cuts gastric‑cancer deaths by 53%, offers a safer profile, and may reshape pricing, reimbursement, and hospital delivery strategies.

Roche’s new KRAS G12C inhibitor divarasib shows 55% risk reduction and 12‑month PFS in advanced NSCLC, outperforming first‑gen drugs with a safer profile.

Discover why Novartis’ solid balance sheet, digital health gains, and strategic M&A give investors a defensive edge in 2024’s pharma landscape.

IncYTE’s SoloTx ADCs show breakthrough HER2 and bispecific tumor targeting, with phase‑2 IBI354 achieving 46% ORR and phase‑1 IBI3001 delivering 28% ORR and manageable safety.

Qiagen’s potential takeover bid: deep dive into its DNA‑diagnostics strengths, valuation premium, and hidden risks & opportunities for investors.

Japanese trials show early safety and 40% disease control for DLL3‑BiTE in SCLC, while a novel mesothelin ADC enters phase II, highlighting Daiichi Sankyo’s next‑gen immuno‑oncology strategy.

Roivant Sciences’ 9 Nov 2026 update: rising revenue amid projected losses, with breakthrough clinical milestones driving new partnership income and future growth prospects.

Amgen’s bispecific Imdelltra + Imfinzi boosts overall survival in extensive‑stage small cell lung cancer by 56%, adding 8 months and redefining first‑line therapy.